

## DOCTORAL THESIS

### Study of a novel curcumin-derived TFEB activator C1 on experimental alzheimer's disease

Malampati, Sandeep

*Date of Award:*  
2020

[Link to publication](#)

#### General rights

Copyright and intellectual property rights for the publications made accessible in HKBU Scholars are retained by the authors and/or other copyright owners. In addition to the restrictions prescribed by the Copyright Ordinance of Hong Kong, all users and readers must also observe the following terms of use:

- Users may download and print one copy of any publication from HKBU Scholars for the purpose of private study or research
- Users cannot further distribute the material or use it for any profit-making activity or commercial gain
- To share publications in HKBU Scholars with others, users are welcome to freely distribute the permanent URL assigned to the publication

## ABSTRACT

Autophagy is the major cellular, conservative, lysosomal catabolic process to eliminate and recycle intracellular waste and organelles through autophagosomes. Enhancing autophagy to promote the clearance of toxic proteins is developing as a promising approach to treat proteinopathy disorders like Alzheimer's disease (AD). AD is the most common aging-associated neurodegenerative disease. It is characterized by the aggregation of aberrantly hyperphosphorylated tau (p-Tau) and excessively produced Amyloid-beta (A $\beta$ ) into neurofibrillary tangles (NFTs), and amyloid plaques (AP) respectively. Reprogramming autophagy lysosomal pathway (ALP) through autophagy master controller, transcription factor EB (TFEB), is developing as an attractive strategy to treat AD. It is already proven that TFEB overexpression can promote A $\beta$  and p-Tau lysosomal clearance, attenuate NFT and AP deposition and restore the behavioural deficits in AD mice models. Previously Song et al., 2016 have identified a small molecule curcumin derivative C1. They reported that C1 could bind to recombinant TFEB and enhance ALP both *in vitro* and *in vivo* conditions independent of mTOR inhibition. In the current study, C1 is systematically evaluated for its bioavailability, anti-AD efficacy *in vitro*, and *in vivo* AD experimental models.

To validate TFEB mediated anti-AD efficacy of C1 *in vitro*, we tested the C1 effect on amyloid precursor protein (APP) and p-Tau degradation *in vitro* neuronal AD cell culture models. In N2a cells overexpressed with APP (695) and EGFP-*P301L* tau plasmids, C1 induced APP, CTF $\beta$ , and Tau lysosomal degradation. To demonstrate the TFEB dependent autophagic clearance effects of C1, TFEB is silenced in N2a cells with lentiviral shRNA

particles. Under TFEB silenced condition, C1 induced reduction of FL-APP, CTF $\beta$ , and Tau was compromised. Overall *In vitro* experiments show that C1 induced lysosomal digestion of FL-APP, CTF $\beta$ , and p-Tau in a TFEB dependent manner.

To further demonstrate C1 brain bioavailability, C1 and curcumin comparative pharmacokinetic studies (Pk study) in both mice (time course Pk study) and rat (single time point analysis) are conducted. In Pk studies, both C1 and curcumin are dosed at 10 mg/kg to determine their concentration in the whole brain (mice), separate brain regions (rat), CSF (rat), and plasma. The WinNonlin analysis of C1 and curcumin mice Pk study data revealed that C1 is significantly more bioavailable than curcumin in both brain and plasma, which is also corroborated by the single time point analysis in rats. To illustrate C1 anti-AD activity *in vivo*, C1 is screened in homozygous P301S (Tau), heterozygous 5xFAD (A $\beta$ ), and homozygous 3xTg (both A $\beta$  and Tau) AD transgenic mice models. These mice were started to treat with C1 before the onset of AD pathology until the AD pathological phenotype is expressed to cause impairment in mice behaviour. In mice behavioural examination, C1 treatment has significantly improved mice motor function (Rotarod-P301S), restored cognitive impairment related to the cortex (contextual fear conditioning-5xFAD), hippocampus (Morris water maze-3xTg) and improved cholinergic activation (open field-3xTg). In the brain biochemical examination, C1 activated the TFEB mediated ALP pathway to degrade FL-APP, CTF $\alpha/\beta$ , A $\beta$ , and p-Tau and reduced the amyloid plaque load, extra neuronal-NFT

positive cells. Notably, C1 treatment in 5xFAD mice has significantly restored hippocampal synaptic function.

In summary, the current study validates C1 as an orally bio-available potent small molecule TFEB activator which restores mice cognitive impairment, altered behaviour, and synaptic plasticity by reducing A $\beta$  and tau levels in AD experimental models. Overall, the TFEB activator C1 can be a promising drug to treat AD.

**Key words:** Alzheimer's disease, Curcumin derivative C1, Autophagy, TFEB.

# TABLE OF CONTENTS

<b>DECLARATION</b> .....	<b>i</b>
<b>ABSTRACT</b> .....	<b>ii</b>
<b>ACKNOWLEDGMENTS</b> .....	<b>v</b>
<b>TABLE OF CONTENTS</b> .....	<b>vii</b>
<b>LIST OF FIGURES</b> .....	<b>xiii</b>
<b>LIST OF TABLES</b> .....	<b>xvi</b>
<b>LIST OF ABBREVIATIONS</b> .....	<b>xvii</b>
<b>CHAPTER 1. Introduction</b> .....	<b>1</b>
<b>1.1 Alzheimer’s disease</b> .....	<b>1</b>
<b>1.1.1 Alzheimer’s disease epidemiology</b> .....	<b>1</b>
<b>1.1.2 AD pathology, diagnosis and treatment</b> .....	<b>2</b>
<b>1.1.3 Pathophysiology of AD</b> .....	<b>3</b>
<b>1.2 Familial Alzheimer’s disease (FAD)</b> .....	<b>4</b>
<b>1.2.1 <math>\beta</math>-Amyloid Precursor Protein (APP)</b> .....	<b>5</b>
1.2.1.1 APP proteolytic processing:.....	6
1.2.1.2 APP trafficking: .....	7
<b>1.2.2 Presenilin-1</b> .....	<b>9</b>
<b>1.2.3 Presenilin-2</b> .....	<b>10</b>
<b>1.2.4 Tau</b> .....	<b>11</b>
<b>1.3 Autophagy</b> .....	<b>13</b>
<b>1.3.1 Macro-autophagy</b> .....	<b>14</b>
1.3.1.1 Autophagy Initiation and autophagosome biogenesis .....	14
1.3.1.2 Substrate recognition .....	15

1.3.1.3 Autophagosome-Lysosome fusion .....	16
<b>1.3.2 Autophagy impairment in AD .....</b>	<b>17</b>
1.3.2.1 Endosome-lysosomal system impairment in AD .....	17
<b>1.4 Chaperone-mediated autophagy (CMA).....</b>	<b>19</b>
<b>1.5 Autophagy modulation as a therapeutic target.....</b>	<b>19</b>
1.5.1 TFEB .....	20
1.5.2 Autophagy reprogramming drugs.....	22
<b>1.6 Curcumin .....</b>	<b>24</b>
<b>1.7 Curcumin derivative C1 .....</b>	<b>26</b>
<b>CHAPTER 2. Hypothesis and Objectives .....</b>	<b>29</b>
<b>CHAPTER 3. PHARMACOKINETIC STUDY OF CURCUMIN DERIVATIVE C1 IN COMPARISON WITH CURCUMIN .....</b>	<b>31</b>
<b>3.1 Introduction .....</b>	<b>31</b>
<b>3.2 Materials and methods .....</b>	<b>32</b>
3.2.1 Animals and treatment .....	32
3.2.2 Cerebrospinal fluid (CSF) collection.....	33
3.2.3 Brain sample processing:.....	34
3.2.4 Plasma and CSF sample processing .....	34
3.2.5 LC-MS/MS condition.....	35
3.2.6 Preparation of stock solutions and calibration of standards .....	36
3.2.7 Statistical analysis.....	36
<b>3.3 Results .....</b>	<b>36</b>
3.3.1 C1 and curcumin bioavailability in mice.....	36
3.3.2 C1 and curcumin single time point oral bioavailability study in rat.....	40
<b>3.4 Discussion.....</b>	<b>41</b>

<b>CHAPTER 4. EFFECT OF CURCUMIN DERIVATIVE C1 ON APP AND A<math>\beta</math> DEGRADATION <i>IN VITRO</i> AND <i>IN VIVO</i> .....</b>	<b>44</b>
<b>4.1 Introduction .....</b>	<b>44</b>
<b>4.2 Materials and methods .....</b>	<b>46</b>
<b>4.2.1 Reagents and antibodies .....</b>	<b>46</b>
<b>4.2.2 Cell-culture .....</b>	<b>47</b>
4.2.2.1 Transfection protocol .....	47
4.2.2.2 Silencing protocol .....	48
4.2.2.3 Cells treatment .....	48
<b>4.2.3 5xFAD mice and treatment .....</b>	<b>49</b>
4.2.3.1 Contextual fear conditioning .....	50
4.2.3.2 Animal Sacrifice.....	51
4.2.3.3 Western blot protocol .....	51
4.2.3.4 Immunohistochemistry.....	52
4.2.3.5 ELISA assay.....	52
<b>4.2.4 C1 efficacy in restoring synaptic plasticity in 5xFAD mice</b>	<b>54</b>
4.2.4.1 5xFAD Mice treatment.....	54
4.2.4.2 Electrophysiological recordings with micro-electrode array recording system .....	54
<b>4.3 RESULTS:.....</b>	<b>55</b>
<b>4.3.1 C1 treatment reduces APP and CTF<math>\beta</math> in SweAPP overexpressed N2a cells.....</b>	<b>55</b>
<b>4.3.2 C1 induces lysosomal degradation of APP and CTF<math>\beta</math> .....</b>	<b>57</b>
<b>4.3.3 C1 induced APP/CTF<math>\beta</math> reduction requires TFEB .....</b>	<b>58</b>
<b>4.3.4 C1 activates TFEB, degrades APP, A<math>\beta</math> and ameliorates memory impairment in 5xFAD mice.....</b>	<b>60</b>
<b>4.3.5 C1 restores hippocampal Synaptic Plasticity in 5xFAD mice .....</b>	<b>72</b>

<b>4.4 DISCUSSION.....</b>	<b>73</b>
<b>CHAPTER 5. Effect of curcumin derivative C1 in P301S mice .....</b>	<b>76</b>
<b>5.1 Introduction.....</b>	<b>76</b>
<b>5.2 Materials and Methods .....</b>	<b>79</b>
<b>5.2.1 Reagents and antibodies .....</b>	<b>79</b>
<b>5.2.2 Cell-culture.....</b>	<b>80</b>
5.2.2.1 Transfection protocol.....	80
5.2.2.2 Silencing protocol .....	81
5.2.2.3 Cells treatment .....	81
<b>5.2.3 Animals and treatment .....</b>	<b>82</b>
5.2.3.1 C1 oral administration in P301S mice .....	82
5.2.3.2 Rota rod experiment.....	83
5.2.3.3 Tissue extraction and Western blotting analysis.....	83
5.2.3.4 Immunohistochemistry.....	84
<b>5.2.4 Statistical analysis.....</b>	<b>84</b>
<b>5.3 RESULTS.....</b>	<b>85</b>
<b>5.3.1 C1 treatment reduces aberrant tau <i>in vitro</i> .....</b>	<b>85</b>
<b>5.3.2 C1 induces lysosomal degradation of aberrant tau.....</b>	<b>86</b>
<b>5.3.3 C1 induced tau degradation requires TFEB .....</b>	<b>87</b>
<b>5.3.4 Effect of C1 in homozygous P301s mice-tauopathy model</b>	<b>88</b>
5.3.4.1 C1 treatment alleviates motor impairment in homozygous P301S mice .....	88
5.3.4.2 C1 reduces p-Tau epitopes by enhancing ALP in P301S mice.....	89
5.3.4.3 C1 reduces sarkosyl insoluble tau in P301S tau mice .....	93
5.3.4.4 C1 reduced NFTs in P301S mice .....	95
<b>5.4 DISCUSSION.....</b>	<b>97</b>



<b>CHAPTER 6. STUDY OF C1 IN TRIPLE TRANSGENIC AD MICE</b>	
<b>MODEL 3xTg.....</b>	<b>102</b>
<b>6.1 Introduction.....</b>	<b>102</b>
<b>6.2 Materials and Methods .....</b>	<b>104</b>
<b>6.2.1 Reagents and antibodies .....</b>	<b>104</b>
<b>6.2.2 Animals and treatment .....</b>	<b>104</b>
6.2.2.1 3xTg mice C1 oral administration and behavioural assessment .....	105
6.2.2.2 Open-field test .....	105
6.2.2.3 Morris-water maze.....	106
6.2.2.4 Tissue extraction and Western blotting analysis.....	107
6.2.2.5 Immunohistochemistry.....	107
6.2.2.6 Statistical analysis .....	108
<b>6.3. C1 effect on 3xTG triple transgenic mice model.....</b>	<b>108</b>
6.3.1 C1 improves open field exploratory behaviour in female 3xTg mice.....	109
6.3.2 C1 restores learning and cognitive impairments in Morris water maze spatial memory learning.....	111
6.3.3 C1 reduces p-Tau, APP, CTFs by promoting ALP in female 3xTg mice.....	113
6.3.4 C1 reduces A $\beta$ plaque load and p-Tau level in female 3xTg mice hippocampus .....	117
<b>6.4 DISCUSSION.....</b>	<b>119</b>
<b>CHAPTER 7. DISCUSSION AND CONCLUSION.....</b>	<b>121</b>
<b>7.1 Targeting ALP as a promising strategy for AD treatment .....</b>	<b>121</b>
<b>7.2 Curcumin and its derivatives anti-AD activity .....</b>	<b>122</b>
<b>7.3 C1 as a promising anti-AD drug candidate.....</b>	<b>123</b>
<b>7.4 Limitations and future study plans .....</b>	<b>126</b>

<b>REFERENCE .....</b>	<b>128</b>
<b>PUBLICATION LIST .....</b>	<b>161</b>
<b>CURRICULUM VITAE .....</b>	<b>167</b>